|
| Introducing Oncotarget |
|
https://doi.org/10.18632/oncotarget.101
Mikhail Blagosklonny, and Andrei Gudkov
|
| 2 |
|
| Shapeshifting and tumor suppression by PLZF |
|
https://doi.org/10.18632/oncotarget.102
Robin M. Hobbs, and Pier Paolo Pandolfi
|
| 3-5 |
|
| Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors |
|
https://doi.org/10.18632/oncotarget.103
Stefan Duensing, and Anette Duensing
|
| 6-8 |
|
| Smooth muscle αactin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation |
|
https://doi.org/10.18632/oncotarget.104
Jin Shi, Minghao Sun, and Peter K. Vogt
|
| 9-21 |
|
| Overexpression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drugresistance |
|
https://doi.org/10.18632/oncotarget.105
Lei Shi, Siqing Wang, Maurizio Zangari, Hongwei Xu, Thai M. Cao, Chunjiao Xu, Yong Wu, Fang Xiao, Yinghong Liu, Ye Yang, Mohamed Salama, Guiyuan Li, Guido Tricot, and Fenghuang Zhan
|
| 22-33 |
|
| Phase 2 clinical trial of 5azacitidine valproic acid and alltrans retinoic acid in patients with highrisk acute myeloid leukemia or myelodysplastic syndrome |
|
https://doi.org/10.18632/oncotarget.106
Emmanuel Raffoux, Audrey Cras, Christian Recher, Pierre-Yves Boëlle, Adrienne de Labarthe, Pascal Turlure, Jean-Pierre Marolleau, Oumedaly Reman, Claude Gardin, Maud Victor, Sébastien Maury, Philippe Rousselot, Jean-Valère Malfuson, Odile Maarek, Marie-Thérèse Daniel, Pierre Fenaux, Laurent Degos, Christine Chomienne, Sylvie Chevret, and Hervé Dombret
|
| 34-42 |
|
| The tumor suppressor p53 connects ribosome biogenesis to cell cycle control: a doubleedged sword |
|
https://doi.org/10.18632/oncotarget.107
Michael Hölzel, Kaspar Burger, Bastian Mühl, Mathias Orban, Markus Kellner, and Dirk Eick
|
| 43-47 |
|
| ID4: a new player in the cancer arena |
|
https://doi.org/10.18632/oncotarget.108
Stefania Dell’Orso, Federica Ganci, Sabrina Strano, Giovanni Blandino, and Giulia Fontemaggi
|
| 48-58 |
|
| A critical role for the NFkB pathway in multiple myeloma |
|
https://doi.org/10.18632/oncotarget.109
Yulia N. Demchenko, and W. Michael Kuehl
|
| 59-68 |
|
| Targeting TOR dependence in cancer |
|
https://doi.org/10.18632/oncotarget.110
Matthew R. Janes, and David A. Fruman
|
| 69-76 |